These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22561369)

  • 1. Risk factors for rate of decline in FEV1 in adults with cystic fibrosis.
    Konstan MW; Wagener JS; Vandevanter DR; Pasta DJ; Yegin A; Rasouliyan L; Morgan WJ
    J Cyst Fibros; 2012 Sep; 11(5):405-11. PubMed ID: 22561369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung function decline from adolescence to young adulthood in cystic fibrosis.
    Vandenbranden SL; McMullen A; Schechter MS; Pasta DJ; Michaelis RL; Konstan MW; Wagener JS; Morgan WJ; McColley SA;
    Pediatr Pulmonol; 2012 Feb; 47(2):135-43. PubMed ID: 22241571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.
    Morgan WJ; Wagener JS; Yegin A; Pasta DJ; Millar SJ; Konstan MW; ;
    J Pediatr; 2013 Oct; 163(4):1152-7.e2. PubMed ID: 23810128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.
    Konstan MW; Morgan WJ; Butler SM; Pasta DJ; Craib ML; Silva SJ; Stokes DC; Wohl ME; Wagener JS; Regelmann WE; Johnson CA;
    J Pediatr; 2007 Aug; 151(2):134-9, 139.e1. PubMed ID: 17643762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project.
    Steinkamp G; Wiedemann B
    Thorax; 2002 Jul; 57(7):596-601. PubMed ID: 12096202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis.
    Ren CL; Konstan MW; Yegin A; Rasouliyan L; Trzaskoma B; Morgan WJ; Regelmann W;
    J Cyst Fibros; 2012 Jul; 11(4):293-9. PubMed ID: 22445849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients.
    Levy H; Kalish LA; Cannon CL; García KC; Gerard C; Goldmann D; Pier GB; Weiss ST; Colin AA
    Pediatr Pulmonol; 2008 May; 43(5):463-71. PubMed ID: 18361452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased rate of lung function decline in Australian adolescents with cystic fibrosis.
    Welsh L; Robertson CF; Ranganathan SC
    Pediatr Pulmonol; 2014 Sep; 49(9):873-7. PubMed ID: 24178906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection.
    Demko CA; Byard PJ; Davis PB
    J Clin Epidemiol; 1995 Aug; 48(8):1041-9. PubMed ID: 7775991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.
    Parad RB; Gerard CJ; Zurakowski D; Nichols DP; Pier GB
    Infect Immun; 1999 Sep; 67(9):4744-50. PubMed ID: 10456926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis.
    McColley SA; Ren CL; Schechter MS; Regelmann WE; Pasta DJ; Konstan MW;
    Pediatr Pulmonol; 2012 Oct; 47(10):966-72. PubMed ID: 22359344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for progression of structural lung disease in school-age children with cystic fibrosis.
    Svedberg M; Gustafsson P; Tiddens H; Imberg H; Pivodic A; Lindblad A
    J Cyst Fibros; 2020 Nov; 19(6):910-916. PubMed ID: 31672554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
    Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
    J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis.
    Schneiderman JE; Wilkes DL; Atenafu EG; Nguyen T; Wells GD; Alarie N; Tullis E; Lands LC; Coates AL; Corey M; Ratjen F
    Eur Respir J; 2014 Mar; 43(3):817-23. PubMed ID: 24176992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis.
    McCauley LA; Thomas W; Laguna TA; Regelmann WE; Moran A; Polgreen LE
    Ann Am Thorac Soc; 2014 Feb; 11(2):198-204. PubMed ID: 24083951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Tai AS; Sherrard LJ; Kidd TJ; Ramsay KA; Buckley C; Syrmis M; Grimwood K; Bell SC; Whiley DM
    BMC Pulm Med; 2017 Nov; 17(1):138. PubMed ID: 29096618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
    Emerson J; Rosenfeld M; McNamara S; Ramsey B; Gibson RL
    Pediatr Pulmonol; 2002 Aug; 34(2):91-100. PubMed ID: 12112774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced survival in adult cystic fibrosis despite attenuated lung function decline.
    Keating C; Poor AD; Liu X; Chiuzan C; Backenroth D; Zhang Y; DiMango E
    J Cyst Fibros; 2017 Jan; 16(1):78-84. PubMed ID: 27522311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis related diabetes in Europe: Prevalence, risk factors and outcome; Olesen et al.
    Olesen HV; Drevinek P; Gulmans VA; Hatziagorou E; Jung A; Mei-Zahav M; Stojnic N; Thomas M; Zolin A;
    J Cyst Fibros; 2020 Mar; 19(2):321-327. PubMed ID: 31680042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.
    VanDevanter DR; Wagener JS; Pasta DJ; Elkin E; Jacobs JR; Morgan WJ; Konstan MW
    Pediatr Pulmonol; 2010 Dec; 45(12):1156-66. PubMed ID: 20717915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.